These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25963424)

  • 21. Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.
    Chen IC; Hsiao LP; Huang IW; Yu HC; Yeh LC; Lin CH; Wei-Wu Chen T; Cheng AL; Lu YS
    Sci Rep; 2017 Aug; 7(1):9842. PubMed ID: 28852212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines.
    Fiedler M; Schulz D; Piendl G; Brockhoff G; Eichberger J; Menevse AN; Beckhove P; Hautmann M; Reichert TE; Ettl T; Bauer RJ
    Exp Cell Res; 2020 Nov; 396(1):112259. PubMed ID: 32898555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
    McRee AJ; Marcom PK; Moore DT; Zamboni WC; Kornblum ZA; Hu Z; Phipps R; Anders CK; Reeder-Hayes K; Carey LA; Weck KE; Perou CM; Dees EC
    Clin Breast Cancer; 2018 Aug; 18(4):289-297. PubMed ID: 29153866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
    Maira SM; Furet P; Stauffer F
    Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Ma CX; Luo J; Naughton M; Ademuyiwa F; Suresh R; Griffith M; Griffith OL; Skidmore ZL; Spies NC; Ramu A; Trani L; Pluard T; Nagaraj G; Thomas S; Guo Z; Hoog J; Han J; Mardis E; Lockhart C; Ellis MJ
    Clin Cancer Res; 2016 Apr; 22(7):1583-91. PubMed ID: 26563128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.
    Myers AP
    Clin Cancer Res; 2013 Oct; 19(19):5264-74. PubMed ID: 24089439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    Slomovitz BM; Coleman RL
    Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
    Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
    Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
    Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
    Blazquez R; Wlochowitz D; Wolff A; Seitz S; Wachter A; Perera-Bel J; Bleckmann A; Beißbarth T; Salinas G; Riemenschneider MJ; Proescholdt M; Evert M; Utpatel K; Siam L; Schatlo B; Balkenhol M; Stadelmann C; Schildhaus HU; Korf U; Reinz E; Wiemann S; Vollmer E; Schulz M; Ritter U; Hanisch UK; Pukrop T
    Glia; 2018 Nov; 66(11):2438-2455. PubMed ID: 30357946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
    Wang S; Niu X; Bao X; Wang Q; Zhang J; Lu S; Wang Y; Xu L; Wang M; Zhang J
    Oncol Rep; 2019 May; 41(5):2636-2646. PubMed ID: 30896825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
    Borson-Chazot F; Dantony E; Illouz F; Lopez J; Niccoli P; Wassermann J; Do Cao C; Leboulleux S; Klein M; Tabarin A; Eberle MC; Benisvy D; de la Fouchardière C; Bournaud C; Lasolle H; Delahaye A; Rabilloud M; Lapras V; Decaussin-Petrucci M; Schlumberger M
    Thyroid; 2018 Sep; 28(9):1174-1179. PubMed ID: 30105951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.
    O'Regan R; Hawk NN
    Expert Opin Ther Targets; 2011 Jul; 15(7):859-72. PubMed ID: 21476875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma.
    Speranza MC; Nowicki MO; Behera P; Cho CF; Chiocca EA; Lawler SE
    Sci Rep; 2016 Feb; 6():20189. PubMed ID: 26846842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antihormonal therapy in breast cancer and mTOR inhibitors].
    Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T
    Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.
    Keck S; Glencer AC; Rugo HS
    Future Oncol; 2012 Nov; 8(11):1383-96. PubMed ID: 23148612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
    Vansteenkiste JF; Canon JL; De Braud F; Grossi F; De Pas T; Gray JE; Su WC; Felip E; Yoshioka H; Gridelli C; Dy GK; Thongprasert S; Reck M; Aimone P; Vidam GA; Roussou P; Wang YA; Di Tomaso E; Soria JC
    J Thorac Oncol; 2015 Sep; 10(9):1319-1327. PubMed ID: 26098748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.